Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Acute exacerbation in fibrotic interstitial lung disease: an international working group report. Local targets link to admitted publications; unresolved targets remain external evidence.
Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report
10.1164/rccm.201604-0801ci · 2016 · External reference
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
10.1016/s2213-2600(20)30554-3 · 2021 · External reference
Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety
10.1136/thorax-2022-219795 · 2023 · External reference
Acute exacerbations in patients with progressive pulmonary fibrosis
10.1183/23120541.00403-2024 · 2024 · External reference
Nintedanib in progressive fibrosing interstitial lung diseases
10.1056/nejmoa1908681 · 2019 · External reference
Nerandomilast in patients with progressive pulmonary fibrosis
10.1056/nejmoa2503643 · 2025 · External reference
Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?
10.1186/s13054-018-2002-4 · 2018 · External reference
Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis
10.1126/sciadv.aba1983 · 2020 · External reference
Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis
10.1164/rccm.201712-2410oc · 2019 · External reference
Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis
10.1164/rccm.202306-0979oc · 2024 · External reference
Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways
10.1152/physrev.00004.2016 · 2016 · External reference
Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis
10.1164/rccm.201809-1650oc · 2019 · External reference
Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis
10.1164/rccm.200810-1596oc · 2009 · External reference
Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis
10.1371/journal.pone.0127771 · 2015 · External reference
Angiopoietin-2 expression in patients with an acute exacerbation of idiopathic interstitial pneumonias
10.1016/j.rmed.2016.05.012 · 2016 · External reference
Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis
10.1186/s13000-016-0583-2 · 2016 · External reference
Elevated expression of growth differentiation factor-15 is associated with acute exacerbation of idiopathic pulmonary fibrosis
10.3389/fimmu.2022.891448 · 2022 · External reference
The NLRP3-inflammasome-caspase-1 pathway is upregulated in idiopathic pulmonary fibrosis and acute exacerbations and is inducible by apoptotic A549 cells
10.3389/fimmu.2021.642855 · 2021 · External reference
Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis
10.1371/journal.pone.0116775 · 2015 · External reference
High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations
10.1016/j.cyto.2017.08.019 · 2018 · External reference
Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin
10.1136/bmjresp-2021-000889 · 2021 · External reference
Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis
10.1016/j.intimp.2019.02.039 · 2019 · External reference
Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis
10.1016/j.resinv.2021.05.008 · 2021 · External reference
Variations in S100A8/A12 gene expression are associated with the efficacy of nintedanib and acute exacerbation development in idiopathic pulmonary fibrosis patients
10.1165/rcmb.2023-0054le · 2023 · External reference
Plasma leptin is elevated in acute exacerbation of idiopathic pulmonary fibrosis
10.1155/2016/6940480 · 2016 · External reference
Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis
10.1038/s41598-019-46990-3 · 2019 · External reference
Serum soluble toll-like receptor 4 is a predictive biomarker for acute exacerbation and prognosis of idiopathic pulmonary fibrosis: a retrospective study
10.1007/s00408-025-00800-y · 2025 · External reference
AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis
10.1111/resp.12995 · 2017 · External reference
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
10.1186/s12931-017-0511-3 · 2017 · External reference
Acute exacerbations of idiopathic pulmonary fibrosis: does clinical stratification or steroid treatment matter?
10.1177/1479973119869334 · 2019 · External reference
10.1016/j.jhlto.2023.100011 · 2023 · Admitted local publication
Significant bacterial isolates in patients presenting with acute exacerbation of idiopathic pulmonary fibrosis
2018 · External reference
Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias
10.36141/svdld.v39i4.13682 · 2022 · External reference
Utility of illness severity scores to predict mortality in patients hospitalized with respiratory deterioration of idiopathic pulmonary fibrosis
10.1093/qjmed/hcaa214 · 2021 · External reference
Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department
2021 · External reference
Clinical characteristics based on the new criteria of acute exacerbation in patients with idiopathic pulmonary fibrosis
10.5152/eurasianjmed.2018.17330 · 2018 · External reference
Direct hemoperfusion with polymyxin B–immobilized fiber for the treatment of the acute exacerbation of idiopathic pulmonary fibrosis in patients requiring invasive mechanical ventilation
10.1016/j.resinv.2017.05.001 · 2017 · External reference
Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease
10.1016/j.rmed.2021.106534 · 2021 · External reference
Acute respiratory deterioration in rheumatoid arthritis–associated interstitial lung disease: a single-center study
10.1016/j.chest.2022.01.007 · 2022 · External reference
Treatment outcomes of infectious and non-infectious acute exacerbation of myositis-related interstitial lung disease
10.3389/fmed.2021.801206 · 2021 · External reference
Bacteriological profile of acute exacerbation of IPF
2023 · External reference
Clinical evaluation of acute exacerbation of interstitial lung disease in a single tertiary center: perspectives before and after the coronavirus disease 2019 pandemic
10.3390/jcm13195733 · 2024 · External reference
Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis
10.1016/j.rmed.2018.09.011 · 2018 · External reference
The role of infection in acute exacerbation of idiopathic pulmonary fibrosis
10.1155/2019/5160694 · 2019 · External reference
Value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in acute exacerbation of fibrosing interstitial lung disease: an individualized treatment protocol based on microbiological evidence
10.1186/s12890-024-03216-1 · 2024 · External reference
Infectious respiratory pathogens among patients with acute exacerbation of idiopathic pulmonary fibrosis during the coronavirus disease 2019 pandemic in Japan
10.1016/j.hrtlng.2024.03.007 · 2024 · External reference
Clinical characteristics of acute exacerbations of idiopathic pulmonary fibrosis and involvement of viral, Mycoplasma pneumoniae, and Chlamydophila pneumoniae infections
2013 · External reference
COVID-19-triggered acute exacerbation of IPF, an underdiagnosed clinical entity with two-peaked respiratory failure: a case report and literature review
10.3389/fmed.2022.815924 · 2022 · External reference
Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019
10.1016/j.rmcr.2022.101615 · 2022 · External reference
Tocilizumab and baricitinib for recovery from acute exacerbation of combined pulmonary fibrosis and emphysema secondary to COVID-19 infection: a case report
10.7759/cureus.23411 · 2022 · External reference
COVID-19 causing acute deterioration of interstitial lung disease: a case report
10.1186/s43055-021-00431-2 · 2021 · External reference
Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study
10.1186/s12931-019-1247-z · 2019 · External reference
COVID-19 and acute exacerbation of interstitial lung disease
10.1016/j.resinv.2021.06.007 · 2021 · External reference
Steroid therapy in acute exacerbation of fibrotic interstitial lung disease
10.1111/resp.14763 · 2024 · External reference
Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis
10.21037/jtd-20-1658 · 2020 · External reference
Successful treatment of infection-triggered acute exacerbation of idiopathic pulmonary fibrosis with corticosteroids combined with macrolides
2019 · External reference
Successful treatment with high-dose steroids for acute exacerbation of idiopathic pulmonary fibrosis triggered by COVID-19
10.2169/internalmedicine.8163-21 · 2022 · External reference
Prevalence of viral infection in acute exacerbation of interstitial lung diseases in Japan
10.1016/j.resinv.2020.06.006 · 2020 · External reference
Exacerbation of hypersensitivity pneumonitis induced by COVID-19
10.1093/qjmed/hcad021 · 2023 · External reference
Fatal acute exacerbation of familial interstitial pneumonia complicated with dyskeratosis congenita after influenza virus B infection
10.2169/internalmedicine.2413-18 · 2019 · External reference
Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia
10.1016/j.resinv.2013.07.005 · 2014 · External reference
High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis
10.1177/1753466619847130 · 2019 · External reference
Viral infection in acute exacerbation of idiopathic pulmonary fibrosis
10.1164/rccm.201010-1752oc · 2011 · External reference
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: what is the best practice for treatment?
10.1016/j.rmcr.2023.101857 · 2023 · External reference
Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report
10.1186/s13104-016-2052-0 · 2016 · External reference
Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis
10.1186/s12931-014-0109-y · 2014 · External reference
Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema
10.1016/j.rmcr.2018.01.004 · 2018 · External reference
Risk factors for acute exacerbation following bronchoalveolar lavage in patients with suspected idiopathic pulmonary fibrosis: a retrospective cohort study
10.5603/arm.a2021.0012 · 2021 · External reference
Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients
10.1620/tjem.174.379 · 1994 · External reference
Acute exacerbation of IPF following bronchoalveolar lavage procedures
10.1378/chest.1108443 · 2011 · External reference
18F-FDG accumulation at the early onset of acute exacerbation of idiopathic interstitial pneumonia on 18F-FDG PET/CT: a case report
10.1002/rcr2.1427 · 2024 · External reference
Risk factors for acute exacerbation of idiopathic interstitial pneumonia in patients undergoing lung cancer treatment
10.1093/jjco/hyz115 · 2019 · External reference
Low bleeding rates following transbronchial lung cryobiopsy in unclassifiable interstitial lung disease
10.1111/resp.14678 · 2024 · External reference
Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients
10.1186/s12890-019-0780-3 · 2019 · External reference
Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis
10.1164/rccm.201504-0711oc · 2016 · External reference
Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis
10.1186/s12931-016-0400-1 · 2016 · External reference
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status
10.21037/jtd.2016.03.89 · 2016 · External reference
Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary fibrosis and emphysema: a retrospective study
10.1097/md.0000000000011683 · 2018 · External reference
Monocyte count and the risk for acute exacerbation of fibrosing interstitial lung disease: a retrospective cohort study
10.1177/1479973120909840 · 2020 · External reference
Cluster features in fibrosing interstitial lung disease and associations with prognosis
10.1186/s12890-023-02735-7 · 2023 · External reference
Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome
10.36141/svdld.v36i1.7117 · 2019 · External reference
Acute exacerbation in interstitial lung disease
10.4103/atm.atm_14_21 · 2021 · External reference
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases
10.1371/journal.pone.0255365 · 2021 · External reference
Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis
10.21037/jtd-21-1418 · 2022 · External reference
Risk factors of acute exacerbation of idiopathic pulmonary fibrosis
2010 · External reference
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
10.1136/bmjresp-2023-001864 · 2023 · External reference
Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia
10.1111/resp.12862 · 2016 · External reference
Impact of the revised definition on incidence and outcomes of acute exacerbation of idiopathic pulmonary fibrosis
10.1038/s41598-022-12693-5 · 2022 · External reference
Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone
10.1016/j.resinv.2019.07.003 · 2019 · External reference
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
10.1183/23120541.00261-2019 · 2020 · External reference
Risk factors for acute exacerbation of idiopathic pulmonary fibrosis-extended analysis of pirfenidone trial in Japan
10.1016/j.resinv.2015.04.005 · 2015 · External reference
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis
10.1093/rheumatology/keaa608 · 2021 · External reference
Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and outcomes
10.1186/s12931-021-01748-2 · 2021 · External reference
Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?
10.1183/13993003.02465-2018 · 2020 · External reference
Identification of risk factors for acute exacerbation of idiopathic pulmonary fibrosis based on baseline high-resolution computed tomography: a prospective observational study
10.1186/s12890-024-03172-w · 2024 · External reference
A predictive model for acute exacerbation of idiopathic interstitial pneumonias
10.1183/13993003.01634-2022 · 2023 · External reference
Association between environment pollution exposure and exacerbation in patients with interstitial lung disease
2024 · External reference
Exposure to PM2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a case-control study
10.1186/s12931-021-01671-6 · 2021 · External reference
Long-term personal air pollution exposure and risk for acute exacerbation of idiopathic pulmonary fibrosis
10.1186/s12940-021-00786-z · 2021 · External reference
Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure
10.1183/09031936.00122213 · 2014 · External reference
Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis
10.1136/thoraxjnl-2017-209967 · 2018 · External reference
Prognosis and survival in idiopathic pulmonary fibrosis in the era of antifibrotic therapy in Italy: evidence from a longitudinal population study based on healthcare utilization databases
10.3390/ijerph192416689 · 2022 · External reference
A clinical model for the prediction of acute exacerbation risk in patients with idiopathic pulmonary fibrosis
10.1155/2020/8848919 · 2020 · External reference
Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis
10.1183/09031936.00050911 · 2012 · External reference
Real-world safety, tolerability and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of post-marketing surveillance in Japan
10.1007/s12325-024-03079-2 · 2025 · External reference
Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study
10.1136/bmjopen-2013-003132 · 2013 · External reference
Long-term outcome of interstitial lung disease in patients with primary Sjögren’s syndrome: a retrospective observational study
10.3904/kjim.2023.402 · 2025 · External reference
Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease
10.1016/j.rmed.2017.05.009 · 2017 · External reference
Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: comparison with idiopathic pulmonary fibrosis
10.1016/j.rmed.2022.106898 · 2022 · External reference
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
10.1183/13993003.02414-2022 · 2023 · External reference
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study
10.1136/bmjresp-2023-002116 · 2024 · External reference
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
10.1186/s12890-021-01530-6 · 2021 · External reference
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
10.1016/j.rmed.2014.04.009 · 2014 · External reference
Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis–associated interstitial lung disease
10.1080/14397595.2021.1879346 · 2021 · External reference
A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema
10.1136/bmjopen-2012-000988 · 2012 · External reference
The risk factors of exacerbation in interstitial pneumonia with autoimmune features: a single-center observational cohort study
10.1007/s40744-021-00371-3 · 2021 · External reference
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
10.1183/09031936.00159709 · 2011 · External reference
Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study
10.1136/bmjresp-2018-000342 · 2018 · External reference
Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases
10.1136/bmjresp-2023-001997 · 2024 · External reference
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases
10.3390/diagnostics11091623 · 2021 · External reference
Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis
10.1183/23120541.00037-2021 · 2021 · External reference
The impact of chronic comorbidities on outcomes in acute exacerbations of idiopathic pulmonary fibrosis
10.3390/life14010156 · 2024 · External reference
Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis
10.1111/resp.14643 · 2024 · External reference
Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease
10.1038/s41598-022-08965-9 · 2022 · External reference
Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
10.1038/s41598-023-39101-w · 2023 · External reference
New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis
10.1038/s41598-022-05138-6 · 2022 · External reference
Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis
10.1038/s41598-020-67598-y · 2020 · External reference
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
10.1186/s12890-017-0437-z · 2017 · External reference
The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia
10.1371/journal.pone.0212810 · 2019 · External reference
Prognostic value of the qSOFA in patients with acute exacerbation of idiopathic pulmonary fibrosis
10.1016/j.resinv.2023.02.006 · 2023 · External reference
Assessing the efficacy of haemoperfusion for dermatomyositis-associated acute exacerbation of interstitial lung disease: a multicentre retrospective study
10.1093/mr/roae066 · 2025 · External reference
Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis
10.1164/rccm.200709-1365oc · 2008 · External reference
Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis
10.3390/medicina55050132 · 2019 · External reference
Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis
10.1111/crj.13304 · 2021 · External reference
HRCT findings predict 1-year mortality in patients with acute exacerbation of idiopathic inflammatory myopathies-associated interstitial lung disease
10.1016/j.heliyon.2024.e31510 · 2024 · External reference
The extent of honeycombing on computed tomography cannot predict the treatment outcome of patients with acute exacerbations of interstitial lung disease
10.1155/2021/7456315 · 2021 · External reference
Prognostic evaluation by oxygenation with positive end-expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: a retrospective cohort study
10.1111/crj.12602 · 2018 · External reference
Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study
10.1038/s41598-021-88718-2 · 2021 · External reference
Computed tomography patterns and clinical outcomes of radiation pneumonitis in non-small-cell lung cancer patients
10.1177/20584601241288502 · 2024 · External reference
Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer
10.1371/journal.pone.0140437 · 2015 · External reference
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review
10.1016/j.semarthrit.2013.09.005 · 2014 · External reference
The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: a systematic review and meta-analysis
10.1016/j.autrev.2023.103335 · 2023 · External reference
Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis
10.3389/fimmu.2025.1628928 · 2025 · External reference
Recognition and management of myositis-associated rapidly progressive interstitial lung disease
10.1016/j.chest.2020.01.033 · 2020 · External reference
Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies
10.1016/j.amjms.2017.07.013 · 2018 · External reference
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases
10.1002/acr.25348 · 2024 · External reference
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.202202-0399st · 2022 · External reference
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement
10.1183/13993003.00158-2025 · 2025 · External reference
Drug-induced interstitial lung disease
10.1183/13993003.02776-2021 · 2022 · External reference
Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia
10.1093/cid/cix317 · 2017 · External reference
Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study
10.1016/j.jinf.2013.03.003 · 2013 · External reference
An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias
10.1164/rccm.201308-1483st · 2013 · External reference
Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.201807-1255st · 2018 · External reference
Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report
10.1016/j.resinv.2014.09.003 · 2015 · External reference
Severe lung injury induced by CD38 monoclonal antibody daratumumab and bortezomib-containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review
10.1111/jcpt.13819 · 2022 · External reference
Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia
10.1016/j.ejcts.2007.02.035 · 2007 · External reference
In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011
10.1164/rccm.201508-1632oc · 2016 · External reference
Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome
10.1016/j.chest.2018.06.027 · 2018 · External reference
Lung transplantation for acute exacerbation of interstitial lung disease
10.1136/thoraxjnl-2020-215681 · 2022 · External reference
Clinical impact of pre-existing acute exacerbation in patients with interstitial lung disease who underwent lung transplantation
10.1186/s12931-023-02614-z · 2023 · External reference
Impact of acute exacerbation of idiopathic pulmonary fibrosis on lung transplant outcomes
10.1097/tp.0000000000004910 · 2024 · External reference
Efficacy of azithromycin for treatment of acute exacerbation of chronic fibrosing interstitial pneumonia: a prospective, open-label study with historical controls
10.1159/000358443 · 2014 · External reference
Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis
10.7150/ijms.4972 · 2013 · External reference
Physiological effects of lung-protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study
10.1186/s13054-023-04682-5 · 2023 · External reference
The use of mechanical ventilation in interstitial lung disease
10.1183/20734735.0172-2024 · 2025 · External reference
Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis
10.2169/internalmedicine.49.3222 · 2010 · External reference
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases
10.1186/1471-2466-14-194 · 2014 · External reference
Noninvasive oxygenation strategies for acute exacerbation of interstitial lung disease: a retrospective single-center study and a review of the literature
10.1097/cpm.0000000000000312 · 2019 · External reference
Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study
10.21037/jtd.2018.12.114 · 2019 · External reference
Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease
10.1177/1753466620906327 · 2020 · External reference
High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study
10.18999/nagjms.82.2.301 · 2020 · External reference
Noninvasive ventilation in acute exacerbation of interstitial lung diseases
10.4103/ecdt.ecdt_40_22 · 2023 · External reference
Comparison between nasal high-flow oxygen therapy and noninvasive ventilation on the outcome of patients with chronic interstitial lung disease complicated with acute respiratory failure
10.4103/ecdt.ecdt_49_23 · 2024 · External reference
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
10.1164/rccm.200404-571oc · 2005 · External reference
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
10.1056/nejmoa1402584 · 2014 · External reference
Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS (R) trials
10.1016/j.rmed.2016.02.001 · 2016 · External reference
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
10.1186/s12931-019-0977-2 · 2019 · External reference
A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis
10.36141/svdld.v37i2.8718 · 2020 · External reference
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
10.1177/1753466620963015 · 2020 · External reference
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital
10.1038/s41598-020-77837-x · 2020 · External reference
Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis
10.1038/s41598-020-72607-1 · 2020 · External reference
Nerandomilast in patients with idiopathic pulmonary fibrosis
10.1056/nejmoa2414108 · 2025 · External reference
Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy
10.1016/j.resinv.2023.01.007 · 2023 · External reference
Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review
10.1136/thorax-2024-222636 · 2025 · External reference
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
10.1164/rccm.2009-040gl · 2011 · External reference
Unresolved reference
2026 · External reference
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s2213-2600(21)00354-4 · 2022 · External reference
Effect of cyclosporine A on mortality after acute exacerbation of idiopathic pulmonary fibrosis
10.21037/jtd.2018.08.08 · 2018 · External reference
Systemic glucocorticoids plus cyclophosphamide for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective nationwide study
10.36141/svdld.v36i2.7181 · 2019 · External reference
Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a propensity score-matched analysis
10.1111/resp.13506 · 2019 · External reference
Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database
10.1016/j.semarthrit.2021.07.008 · 2021 · External reference
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations
10.1371/journal.pone.0260345 · 2021 · External reference
Design of the STRIVE-IPF trial—study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis
10.1186/s12890-024-02957-3 · 2024 · External reference
Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
10.1186/s12890-015-0004-4 · 2015 · External reference
Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a polymyxin B-immobilized fiber column: a retrospective analysis
10.2169/internalmedicine.55.6056 · 2016 · External reference
Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies
10.1177/1753465817708950 · 2017 · External reference
Polymyxin B-immobilised fibre column treatment for acute exacerbation of idiopathic pulmonary fibrosis patients with mechanical ventilation: a nationwide observational study
10.1186/s40560-023-00693-0 · 2023 · External reference
Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
10.2147/dddt.s90739 · 2015 · External reference
Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis
10.1378/chest.14-2746 · 2015 · External reference
Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial
10.1186/s40248-016-0074-z · 2016 · External reference
Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a historically controlled study
10.1016/j.resinv.2017.10.004 · 2018 · External reference
Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. a randomized, double-blind placebo-controlled trial
10.1164/rccm.201909-1818oc · 2020 · External reference
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS trials
10.1186/s12931-019-1037-7 · 2019 · External reference
The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia
10.1111/crj.12704 · 2018 · External reference
Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation
10.1080/03007995.2019.1565530 · 2019 · External reference
Mechanical ventilation for acute exacerbation of fibrosing interstitial lung diseases
10.1016/j.resinv.2023.01.008 · 2023 · External reference
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
10.1186/s12890-021-01607-2 · 2021 · External reference
Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials
10.1001/jama.2023.5355 · 2023 · External reference
Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial
10.1164/rccm.202401-0116oc · 2024 · External reference
Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial
10.1001/jama.2024.8693 · 2024 · External reference
Acute exacerbations of idiopathic pulmonary fibrosis
10.1164/rccm.200703-463pp · 2007 · External reference
Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on “feels, functions, survives.” Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency
10.1164/rccm.202312-2213so · 2024 · External reference
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
10.1183/13993003.01339-2016 · 2017 · External reference
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
10.1183/13993003.01760-2019 · 2020 · External reference
Management of acute exacerbation of idiopathic pulmonary fibrosis in specialised and non-specialised ILD centres around the world
10.3389/fmed.2021.699644 · 2021 · External reference
Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter
10.1378/chest.08-0703 · 2009 · External reference
Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016
10.1186/s12931-020-01421-0 · 2020 · External reference
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis
10.1183/23120541.00636-2023 · 2024 · External reference
Unresolved reference
2025 · External reference
Approach to the evaluation and management of interstitial lung abnormalities: an official American Thoracic Society clinical statement
10.1164/rccm.202505-1054st · 2025 · External reference
Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis
10.18553/jmcp.2016.22.4.414 · 2016 · External reference
